ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Atara Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$8.96−0.22 (-2.40%)
Close on Oct 19, 2026
- Market cap
- $134.70M
- P/E (TTM)
- 3.5
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Operating margin
29.7%
Net margin
27.1%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -6.3% | +23.9% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -27.8% | -81.4% | -48.1% | |
| Return on assets | -26.8% | -65.9% | 50.5% | |
| Current ratio | 26.93 | 6.31 | 0.82 | |
| Interest coverage | – | – | 9.5× | |
| Capex to revenue | – | – | 0.0% | |
| Diluted shares | 1M | 3M | 13M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Atara Biotherapeutics generated $803.59M from operations and spent $16.24M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$803.59M
Used
$16.24M
Capital expenditure$16.24M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin27.1%
×Asset turnover1.87×
×Equity multiplier-0.95×
=Return on equity, FY2025-48.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 27.1% | 1.87× | -0.95× | -48.1% |
| FY2024 | -66.2% | 0.94× | 140.97× | -8768.3% |
| FY2023 | -3220.9% | 0.03× | 2.40× | -244.5% |
| FY2022 | -359.1% | 0.15× | 2.08× | -112.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$32.69M
- Cash generatingOperating cash flow above zero-$50.94M
- Return on assets improvedROA up on the prior year-51.6% → 30.0%
- Earnings backed by cashOperating cash flow above net income-$50.94M vs $32.69M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.48 → 0.82
- No dilutionShare count did not rise7M → 13M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.78 → 1.11